Evaluating Pyrroloquinoline Quinone (PQQ) for Improving Obese Pregnancy Outcomes
Key facts
- Who runs it
- University of Oklahoma
- Where
- Oklahoma City, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Early phase 1
- Started
- Dec 2024
- Ended
- Aug 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Pyrroloquinoline quinone (PQQ)
- Placebo with soybean oil
- Record updated
- 13 February 2025
- Why it stopped
- Investigator did not return submission for final IRB approval. Study was withdrawn by IRB.
Who can take part
- Age
- 18 years to 40 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Adult women
- Body mass index >30 kg/m2
- Currently pregnant with gestational age up to 16 wks
Who cannot take part
- Women with pregestational diabetes (type 1 or type 2)
- Women with other risk factors for placental insufficiency or preterm delivery
- Pre-existing chronic hypertension
- Renal disease
- Human immunodeficiency virus (HIV)
- Hepatitis C
- Autoimmune disorders
- Advanced maternal age (age ≥40 yrs)
- Smokers
- Thrombophilias
- Substance use
Where in United States
- University of Oklahoma Health Sciences CenterOklahoma City, United States
About the trial
What the trial wants to find out
Maternal obesity (MO) affects 1 in 5 women and is strongly linked to increased birth weight, childhood/adolescent obesity, life-long metabolic and inflammatory disorders, and childhood neuropsychiatric disorders. There remains a critical unmet need for developing a safe and effective non-pharmacological approach for attenuating metabolic inflammation and ameliorating the adverse effects of MO on offspring health that originate in utero and extend into the lactational period. Pyrroloquinoline quinone (PQQ) is a diet-derived natural food supplement with anti-inflammatory properties that, in humans and mice, improves metabolism and exerts potent immunoregulatory effects. Researchers' central hypothesis is that PQQ administration during MO pregnancy 1) improves maternal metabolic and inflammatory indices, 2) improves utero-placental blood flow and ameliorates placental maladaptation (oxidative stress, hypoxia, inflammation and fatty acid transporter expression) and 3) reduces neonatal adiposity.
The 2 groups in the trial
- PQQ supplementExisting treatment, for comparison
Pyrroloquinoline quinone (PQQ) 20 mg/day
Treatment: Pyrroloquinoline quinone (PQQ)
- PlaceboPlacebo, for comparison
Placebo supplement with soybean oil 20 mg/day
Treatment: Placebo with soybean oil
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluating Pyrroloquinoline Quinone (PQQ) for Improving Obese Pregnancy Outcomes (EPyQ)
- Record updated
- 13 February 2025